Molecular diagnostics firm Co-Diagnostics has announced it has secured a major intellectual property victory in Japan, as the Japan Patent Office granted a new patent covering core technology behind the company’s next-generation diagnostic platform.

 

The patent, titled “Systems, Methods, and Apparatus for Automated Self-Contained Biological Analysis”—protects critical elements of the company’s Co-Dx PCR Pro point-of-care testing system, including its instrument design and proprietary test cups used for automated biological analysis.

 

Initially registered on December 26, 2025, the patent includes 34 claims and was filed under the Patent Cooperation Treaty framework, allowing the company to pursue coordinated international protection through a single application.

 

“The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process,” said Dwight Egan, Chief Executive Officer of Co-Diagnostics. 

 

“We believe that receiving such a comprehensive patent by the JPO illustrates the uniqueness and innovation of the Co-Dx platform, and its potential for transforming how and where infectious diseases are diagnosed. This patent reinforces the global protection of our platform technologies and supports our strategy to expand access to affordable, high-performance point-of-care PCR testing solutions worldwide.”

 

The new patent follows a similar grant by the Australian Patent Office in 2025, expanding Co-Diagnostics’ growing international patent portfolio aimed at safeguarding its PCR platform across major global markets.

 

By securing intellectual property rights in Japan, the company strengthens its competitive position in Asia and boosts its ability to pursue commercial partnerships, regulatory approvals, and broader market expansion in the region.

 

Co-Diagnostics’ point-of-care PCR system is designed to bring gold-standard PCR accuracy to decentralized settings through a compact, easy-to-use device. The platform is powered by the company’s proprietary Co-Primers technology, enabling rapid, highly sensitive, and precise molecular diagnostics across a wide range of infectious disease applications.

 

The 34 claims within the newly granted patent cover the underlying systems, methods, and hardware enabling automated, self-contained biological analysis, including both the PCR instrument and the specialized disposable test cups used with the platform.